Konova Frequently Asked Questions (FAQ)
Where is Konova's headquarters?
Konova's headquarters is located at Laguna Niguel.
What is Konova's latest funding round?
Konova's latest funding round is Other Investors.
Who are the investors of Konova?
Investors of Konova include Domain Associates.
Who are Konova's competitors?
Competitors of Konova include BioDelivery Sciences International, Amplyx Pharmaceuticals, Ra Pharmaceuticals, SynDevRx, The Medicines Company and 7 more.
Compare Konova to Competitors
SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market and inhibits MetAP2 - an enzyme that independent research has shown to be key to tumor growth, proliferation, and metastasis. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development
Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.
RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.
Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.